The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Open accessAbstract
OBJECTIVE: To assess the evidence for the efficacy of IV immunoglobulin (IVIg) to treat neuromuscular disorders. METHODS: The MEDLINE, Web of Science, and EMBASE databases were searched (1966-2009). Selected articles were rated according to the American Academy of Neurology's therapeutic classification of evidence scheme; recommendations were based on the evidence level. RESULTS AND RECOMMENDATIONS: IVIg is as efficacious as plasmapheresis and should be offered for treating Guillain-Barré syndrome (GBS) in adults (Level A). IVIg is effective and should be offered in the long-term treatment of chronic inflammatory demyelinating polyneuropathy (Level A). IVIg is probably effective and should be considered for treating moderate to severe myasthenia gravis and multifocal motor neuropathy (Level B). IVIg is possibly effective and may be considered for treating nonresponsive dermatomyositis in adults and Lambert-Eaton myasthenic syndrome (Level C). Evidence is insufficient to support or refute use of IVIg in the treatment of immunoglobulin M paraprotein-associated neuropathy, inclusion body myositis, polymyositis, diabetic radiculoplexoneuropathy, or Miller Fisher syndrome, or in the routine treatment of postpolio syndrome or in children with GBS (Level U). IVIg combined with plasmapheresis should not be considered for treating GBS (Level B). More data are needed regarding IVIg efficacy as compared with other treatments/treatment combinations. Most studies concluded IVIg-related serious adverse effects were rare. Given the variable nature of these diseases, individualized treatments depending on patient need and physician judgment are important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Hughes, R. A., Donofrio, P., Bril, V., Dalakas, M. C., Deng, C., Hanna, K., Hartung, H.-P., Latov, N., Merkies, I. S., & van Doorn, P. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70329-0 · Cited by 674
Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., Nobile‐Orazio, E., Van Doorn, P., Dalakas, M., Bojar, M., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1088 · Cited by 628
(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Guidelines for treatment of autoimmune neuromuscular transmission disorders
Skeie, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L., Hilton‐Jones, D., Melms, A., Verschuuren, J., & Horge, H. W. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03019.x · Cited by 515
Hahn, A. F., Bolton, C. F., Zochodne, D., & Feasby, T. E. (1996) · Brain · doi:10.1093/brain/119.4.1067 · Cited by 439
Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
Dalakas, M. C., Sonies, B., Dambrosia, J., Sekul, E., Cupler, E., & Sivakumar, K. (1997) · Neurology · doi:10.1212/wnl.48.3.712 · Cited by 350
Leger, J.-M., Chassande, B., Musset, L., Meininger, V., Bouche, P., & Baumann, N. (2001) · Brain · doi:10.1093/brain/124.1.145 · Cited by 279
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., & Li, T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa102 · Cited by 405
Novel therapeutic approaches in multiple system atrophy
Palma, J.-A., & Kaufmann, H. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0249-7 · Cited by 24
Metadata
- Authors
- Patwa, H. S., Chaudhry, V., Katzberg, H., Rae-Grant, A. D., & So, Y. T.
- Venue
- Neurology
- Published
- 2012-03-27
- Volume
- 78
- Issue
- 13
- Pages
- 1009-1015
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2149347708
- Cited by
- 254
- References
- 24
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. https://app.cochat.ai/papers/10.1212/wnl.0b013e31824de293
- The paper
- Patwa, H. S., Chaudhry, V., Katzberg, H., Rae-Grant, A. D., & So, Y. T. (2012). Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. https://doi.org/10.1212/wnl.0b013e31824de293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.